To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approximately 10 ...

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...

We are excited about the potential for Daré’s Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to ...

DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual ... Daré's Sildenafil Cream has the potential to ...

Studies of selective phosphodiesterase type 5 inhibitors (sildenafil [Viagra], vardenafil [Levitra], and tadalafil [Cialis]) as therapy for women with sexual arousal disorder have produced mixed ...

an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, reflecting U.S. Food and Drug Administration feedback for ...

Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women. SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE ...

an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, FSAD, has been published by Sexual Medicine, an official ...